Insider Selling: Illumina (NASDAQ:ILMN) Director Sells 138,379 Shares of Stock

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 138,379 shares of the stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the sale, the director owned 1,033,910 shares of the company’s stock, valued at $236,651,659.90. This trade represents a 11.80% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Illumina Stock Performance

Shares of Illumina stock traded up $2.85 during trading hours on Thursday, hitting $227.69. 1,937,136 shares of the company were exchanged, compared to its average volume of 2,109,322. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. The business has a 50-day moving average of $192.98 and a 200-day moving average of $155.18. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81. The stock has a market capitalization of $34.38 billion, a price-to-earnings ratio of 42.48, a P/E/G ratio of 3.16 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. Illumina’s revenue was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, analysts expect that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Institutional Trading of Illumina

Several large investors have recently bought and sold shares of ILMN. HighPoint Advisor Group LLC increased its position in shares of Illumina by 3.7% during the fourth quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock worth $291,000 after buying an additional 80 shares during the period. Elevation Wealth Partners LLC lifted its holdings in Illumina by 52.5% in the second quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock valued at $43,000 after buying an additional 84 shares during the period. Meeder Advisory Services Inc. boosted its position in Illumina by 3.1% during the first quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock valued at $348,000 after acquiring an additional 85 shares during the last quarter. Toronto Dominion Bank grew its holdings in Illumina by 0.3% during the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares during the period. Finally, Panagora Asset Management Inc. grew its holdings in Illumina by 3.9% during the 4th quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 96 shares during the period. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on ILMN shares. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Daiwa Securities Group upgraded Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target on the stock in a research note on Thursday, May 14th. Guggenheim increased their price objective on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, June 3rd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $215.00 price target on shares of Illumina in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $188.40.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.